Doxylamine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Doxylamine: Antihistamine (H1 blocker) → nasal cavity disease
One-Sentence Summary
Doxylamine is a first-generation antihistamine with 20 valid licences in Canada. The TxGNN model predicts it may be useful for nasal cavity disease. No clinical trials or publications were found for this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9936 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Doxylamine is an H1-receptor antihistamine with anticholinergic (drying) properties. Both actions could plausibly reduce nasal symptoms such as runny nose and sneezing.
“Nasal cavity disease” is a broad category. The prediction is probably driven by its closeness to nasal conditions already linked to this drug, not by a new mechanism. The term is too nonspecific to define a clear repurposing hypothesis, and no study in the compiled data addresses it directly.
Canada Market Information
Health Canada records show 20 valid single-ingredient licences, and none are cancelled. The list below may be partial. Dosage form and approved-indication text are not recorded in the local data.
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00609129 | DICLECTIN | Not recorded | Not recorded |
| 02413248 | APO-DOXYLAMINE/B6 | Not recorded | Not recorded |
| 02552574 | ALOG-DOXYLAMINE/PYRIDOXINE | Not recorded | Not recorded |
| 02485443 | ROBITUSSIN HONEY COUGH & COLD NIGHTTIME | Not recorded | Not recorded |
| 02406187 | PMS-DOXYLAMINE-PYRIDOXINE | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions (100 interactions found; selected examples):
- Major: potassium citrate, potassium chloride
- Moderate: other anticholinergics (atropine, hyoscyamine, scopolamine, glycopyrronium, dicyclomine), opioids (morphine, opium), loperamide, metoclopramide, dronabinol, nabilone
Package insert warnings and contraindications are not available in the data compiled for this report. Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5), with no clinical trials or publications on nasal cavity disease. The disease term is also too broad to define a testable hypothesis.
To proceed, the following is needed:
- A more specific target condition within nasal cavity disease
- Clinical or literature evidence that directly studies that condition
- Mechanism-of-action data
- Health Canada package insert warnings and contraindications, reviewed before any safety screening
- Review of the major potassium-salt interactions and of additive anticholinergic and sedative effects
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.